Skip to main
LRMR
LRMR logo

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics Inc. has demonstrated promising advancements with its lead product candidate, CTI-1601, evidenced by a significant increase in median frataxin (FXN) expression from 2.7 pg/μg at baseline to 13.44 pg/μg at the six-month mark, indicating the product's potential efficacy in treating Friedreich's ataxia. Additionally, the company reported a median improvement of -2.20 points on the modified Friedreich's Ataxia Rating Scale (mFARS), contrasting with a decline of +1.00 points observed in the FACOMS natural history population over the same period, which underscores the therapeutic benefits of CTI-1601. These compelling clinical results position Larimar Therapeutics favorably within the biotechnology sector, signifying its capacity to address unmet medical needs in the rare disease space.

Bears say

Larimar Therapeutics's financial outlook has been negatively impacted by a significant decrease in its FY29 revenue estimate, lowering from $659 million to $407 million, which raises concerns regarding the company's growth potential in the Friedreich's ataxia market. Additionally, the median change in the modified Friedreich Ataxia Rating Scale (mFARS) demonstrates a concerning decline of -2.20 points over one year for CTI-1601, indicating less favorable outcomes compared to a decline of +1.00 point in the FACOMS natural history population. This disparity in clinical outcomes further compounds the challenges faced by the company in achieving its market share goals, casting doubt on the viability of its lead product candidate.

LRMR has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 7 analysts, LRMR has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.